Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2015

01-08-2015 | Mini Review

The relationship between long-term proton pump inhibitor therapy and skeletal frailty

Authors: Arthur N. Lau, Michael Tomizza, Matthew Wong-Pack, Alexandra Papaioannou, Jonathan D. Adachi

Published in: Endocrine | Issue 3/2015

Login to get access

Abstract

Proton pump inhibitors (PPIs) are a commonly prescribed class of medications. Their use has been associated with an increased rate of fractures, most notably hip fractures. However, there does not seem to be a clear association between PPI use and bone mineral density measurements, assessed by dual X-ray absorptiometry. The mechanism by which PPI use increases the risk of fractures remains unclear. This review will summarize the current evidence on this topic.
Literature
1.
M.L. Schubert, D.A. Peura, Control of gastric acid secretion in health and disease. Gastroenterology 134(7), 1842–1860 (2008)PubMedCrossRef
2.
3.
S. Dial et al., Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294(23), 2989–2995 (2005)PubMedCrossRef
4.
R.J. Laheij et al., Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16), 1955–1960 (2004)PubMedCrossRef
5.
M.D. Howell et al., Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170(9), 784–790 (2010)PubMedCrossRef
6.
A. Deshpande et al., Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin. Gastroenterol. Hepatol. 10(3), 225–233 (2012)PubMedCrossRef
7.
N.R. Rozgony et al., Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J. Nutr. Elder 29(1), 87–99 (2010)PubMedCrossRef
8.
K.L. Insogna, The effect of proton pump-inhibiting drugs on mineral metabolism. Am. J. Gastroenterol. 104(Suppl 2), S2–S4 (2009)PubMedCrossRef
9.
H. Koop, Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment. Pharmacol. Ther. 6(4), 399–406 (1992)PubMedCrossRef
10.
S.A. Wainwright et al., Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 90(5), 2787–2793 (2005)PubMedCrossRef
11.
S.R. Cummings et al., Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332(12), 767–773 (1995)PubMedCrossRef
12.
S.P. Marcuard, L. Albernaz, P.G. Khazanie, Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann. Intern. Med. 120(3), 211–215 (1994)PubMedCrossRef
13.
J.R. Lewis et al., Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J. Bone Miner. Res. 29(11), 2489–2497 (2014)PubMedCrossRef
14.
E. Salgueiro et al., Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int. J. Clin. Pharmacol. Ther. 44(11), 548–556 (2006)PubMedCrossRef
15.
B.M. Kuschel, L. Laflamme, J. Moller, The risk of fall injury in relation to commonly prescribed medications among older people-a Swedish case–control study. Eur. J. Public Health (2014). doi:10.​1093/​eurpub/​cku120
16.
K. Zhu et al., ‘Timed up and go’ test and bone mineral density measurement for fracture prediction. Arch. Intern. Med. 171(18), 1655–1661 (2011)PubMedCrossRef
17.
S.L. Gray et al., Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch. Intern. Med. 170(9), 765–771 (2010)PubMedCentralPubMedCrossRef
18.
L.E. Targownik et al., Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3), 896–904 (2010)PubMedCrossRef
19.
D.H. Solomon et al., Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J. Bone Miner. Res. 30(2), 232–239 (2014)CrossRef
20.
21.
Y.X. Yang et al., Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947–2953 (2006)PubMedCrossRef
22.
B. Abrahamsen, P. Vestergaard, Proton pump inhibitor use and fracture risk—effect modification by histamine H1 receptor blockade. Observational case–control study using national prescription data. Bone 57(1), 269–271 (2013)PubMedCrossRef
23.
J. Ding et al., The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif. Tissue Int. 94(6), 597–607 (2014)PubMedCrossRef
24.
L.M. Moberg et al., Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 78(4), 310–315 (2014)PubMedCrossRef
25.
J. Lee et al., A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J. Gastroenterol. 48(9), 1016–1022 (2013)PubMedCrossRef
26.
D. Prieto-Alhambra et al., Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J. Bone Miner. Res. 29(1), 268–274 (2014)PubMedCrossRef
27.
28.
P. Vestergaard, L. Rejnmark, L. Mosekilde, Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue Int. 79(2), 76–83 (2006)PubMedCrossRef
29.
F. de Vries et al., Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos. Int. 20(12), 1989–1998 (2009)PubMedCrossRef
30.
31.
D.P. Kiel et al., Health care utilization and functional status in the aged following a fall. Med. Care 29(3), 221–228 (1991)PubMedCrossRef
Metadata
Title
The relationship between long-term proton pump inhibitor therapy and skeletal frailty
Authors
Arthur N. Lau
Michael Tomizza
Matthew Wong-Pack
Alexandra Papaioannou
Jonathan D. Adachi
Publication date
01-08-2015
Publisher
Springer US
Published in
Endocrine / Issue 3/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0576-z

Other articles of this Issue 3/2015

Endocrine 3/2015 Go to the issue

Original Article

Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center

Review

Gene interference strategies as a new tool for the treatment of prostate cancer

Pros and Cons in Endocrine Practice

Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros

Research Letter

Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib

Endocrine Genetics/Epigenetics

Associations between a common variant near the MC4R gene and serum triglyceride levels in an obese pediatric cohort

Original Article

Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits